Skip to main content

Table 5 Effect of tolvaptan at baseline and during inhibition of the nitric oxide system on brachial systolic- and diastolic blood pressure (SBP and DBP), and pulse rate in a randomized, placebo-controlled, double-blind, crossover study of 19 healthy subjects

From: Effect of vasopressin antagonism on renal handling of sodium and water and central and brachial blood pressure during inhibition of the nitric oxide system in healthy subjects

Periods Baseline L-NMMA Post infusion p (GLM-within)
  0-90 min 90-120 min 120-150 min 150-180 min 180-210 min
SBP (mmHG)
Placebo 112 ± 8 113 ± 9 115 ± 8* 115 ± 9* 116 ± 10* 0.170
Tolvaptan 112 ± 11 115 ± 9* 116 ± 9* 116 ± 10* 114 ± 9
p (GLM between) 0.876
p (paired t-test, between) 0.833 0.117 0.272 0.929 0.430  
DBP (mmHg)
Placebo 61 ± 5 68 ± 6*** 67 ± 6*** 67 ± 5* 65 ± 7 0.688
Tolvaptan 63 ± 5 69 ± 7*** 68 ± 6*** 67 ± 6 66 ± 7
p(GLM between) 0.606
p (paired t-test, between) 0.049 0.467 0.259 0.907 0.454  
Pulse rate (BPM)
Placebo 57 ± 10 52 ± 9*** 53 ± 9*** 55. ± 11*** 58 ± 12*** 0.889
Tolvaptan 55 ± 10 50 ± 9*** 51 ± 9*** 53 ± 10*** 56 ± 11*
p (GLM between) 0.527
p (paired t-test, between) 0.016 0.022 0.007 0.013 0.003  
  1. Data are shown as mean with ± SD or medians with ± interquartile range. General linear model (GLM) with repeated measures was performed for comparison within the group and intervention as between subjects factor. Post-hoc Bonferoni test (*) was used for comparison of infusion period 90–150 min vs baseline and post infusion period 150–210 vs baseline. Paired t-test or Wilcoxon signed rank test was used for comparison between treatment group at baseline vs during infusion period 90–150 min, and at baseline vs post infusion period 150–210 min. *p < 0.05; **p < 0.001;*** p < 0.0001.